Literature DB >> 2073459

Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells.

G J Kontoghiorghes1, A May.   

Abstract

Iron chelators of different physicochemical properties were studied for their ability to donate iron in vitro to uninduced K562 cells, human bone marrow cells and purified human erythroblasts. To a large extent uptake was found to be related to lipophilicity and those chelators able to deliver iron to the cells in significant amounts were also able to deliver iron to ferritin and haem. Some differences in the distribution of iron delivered was observed but no chelator showed exclusive delivery to or rejection of a particular cellular iron compartment. Several chelators could probably substitute for transferrin and be used to probe metabolic events subsequent to iron removal from transferrin. Two chelators which were excellent iron donors were also found to cause considerable inhibition of iron incorporation into haem from transferrin. The implications of this for in vivo toxicity are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073459     DOI: 10.1007/BF01140577

Source DB:  PubMed          Journal:  Biol Met        ISSN: 0933-5854


  20 in total

1.  Chelators affecting iron absorption in mice.

Authors:  G J Kontoghiorghes
Journal:  Arzneimittelforschung       Date:  1990-12

2.  Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines.

Authors:  G J Kontoghiorghes; A Piga; A V Hoffbrand
Journal:  Hematol Oncol       Date:  1986 Jul-Sep       Impact factor: 5.271

3.  8-hydroxyquinoline: chronic toxicity and inhibitory effect on the carcinogenicity of N-2-fluorenylacetamide.

Authors:  R S Yamamoto; G M Williams; H H Frankel; J H Weisburger
Journal:  Toxicol Appl Pharmacol       Date:  1971-08       Impact factor: 4.219

4.  Use of iron from transferrin and microbial chelates as substrate for heme synthetase in transformed and primary erythroid cell cultures.

Authors:  A Barnekow; G Winkelmann
Journal:  Biochim Biophys Acta       Date:  1978-11-01

5.  A two-step procedure for obtaining normal peripheral blood T-lymphocytes using continuous equilibrium density gradient centrifugation on percoll.

Authors:  F M Ali; A May; G D McLaren; A Jacobs
Journal:  J Immunol Methods       Date:  1982-03-12       Impact factor: 2.303

6.  The mechanism of iron exchange between synthetic iron chelators and rabbit reticulocytes.

Authors:  D Hemmaplardh; E H Morgan
Journal:  Biochim Biophys Acta       Date:  1974-11-27

7.  A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents.

Authors:  P Ponka; J Borová; J Neuwirt; O Fuchs; E Necas
Journal:  Biochim Biophys Acta       Date:  1979-08-22

8.  Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexes.

Authors:  K Forsbeck; K Nilsson; G J Kontoghiorghes
Journal:  Eur J Haematol       Date:  1987-10       Impact factor: 2.997

9.  Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

Authors:  G J Kontoghiorghes; M A Aldouri; A V Hoffbrand; J Barr; B Wonke; T Kourouclaris; L Sheppard
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-12

10.  Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.

Authors:  G J Kontoghiorghes
Journal:  Acta Haematol       Date:  1987       Impact factor: 2.195

View more
  8 in total

1.  Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.

Authors:  Takamasa Nishiuchi; Yuichi Okutani; Toshikazu Fujita; Kazuya Yoshida; Hiroaki Ohnishi; Reiji Haba
Journal:  Int J Hematol       Date:  2010-02-04       Impact factor: 2.490

2.  Dietary and pharmacological factors affecting iron absorption in mice and man (Comment for a Letter to the editor).

Authors:  Christina N Kontoghiorghe; Annita Kolnagou; George J Kontoghiorghes
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

3.  Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.

Authors:  Minoru Kojima; Shinichiro Machida; Ai Sato; Mitsuki Miyamoto; Makiko Moriuchi; Yoshiaki Ohbayashi; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2013-10-26       Impact factor: 2.490

Review 4.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

Review 6.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

7.  Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

Authors:  Anna Angela Di Tucci; Roberta Murru; Daniele Alberti; Bertrand Rabault; Simona Deplano; Emanuele Angelucci
Journal:  Eur J Haematol       Date:  2007-03-28       Impact factor: 2.997

Review 8.  Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.

Authors:  George J Kontoghiorghes; Christina N Kontoghiorghe
Journal:  Cells       Date:  2020-06-12       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.